This narrow cold chain maintains the structural integrity of the semaglutide molecule, ensuring the peptide delivers consistent glucose control and appetite suppression signals to your brain and pancreas
Clinical trials consistently show reductions in total caloric consumption in patients treated with semaglutide and tirzepatide. When energy intake decreases substantially, micronutrient intake may also decline unless food quality remains high
Of 5,988 patients, 2,997 patients were randomized to empagliflozin 10 mg once daily and 2,991 patients to placebo once daily and were followed for a median of 26 months
Currently, in addition to LY3463251, several other GDF-15 agonists are being assessed in early-stage clinical trials, including NNC0247-0829 and JNJ-9090/CIN-109, among others
Stopping might help prevent things from getting worse, but it wont fix whats already happening
You might be losing fat but gaining a bit of muscle from exercise (which is great!)
